Corvus Pharmaceuticals, Inc.
CRVS
$3.24
$0.010.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.82% | 11.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.72% | 22.24% | |||
| Operating Income | -11.72% | -22.24% | |||
| Income Before Tax | 69.88% | -843.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 69.88% | -843.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 69.88% | -843.62% | |||
| EBIT | -11.72% | -22.24% | |||
| EBITDA | -11.76% | -22.32% | |||
| EPS Basic | 70.61% | -744.40% | |||
| Normalized Basic EPS | 70.59% | -744.84% | |||
| EPS Diluted | 70.61% | -744.40% | |||
| Normalized Diluted EPS | 70.59% | -744.84% | |||
| Average Basic Shares Outstanding | 2.47% | 11.71% | |||
| Average Diluted Shares Outstanding | 2.47% | 11.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||